Vol 14, No 2 (2020)
Case report
Published online: 2020-05-29

open access

Page views 833
Article views/downloads 1076
Get Citation

Connect on Social Media

Connect on Social Media

Methadone in the treatment of bone pain in a patient with disseminated breast cancer

Krzysztof Nosek123, Wojciech Leppert4, Łukasz Puchała1, Aleksandra Pawlos1, Dariusz Onichimowski5
Palliat Med Pract 2020;14(2):115-119.

Abstract

Treatment of pain is an important element of therapeutic management in cancer patients. The article presents
the case of a patient diagnosed with breast cancer, which spread to the liver and lungs and presenting
with severe bone pain syndrome caused by lumbosacral metastases. Treatment of pain with non-opioid
analgesics, opioids, analgesic adjuvants and palliative radiotherapy proved ineffective. The addition of
small doses of methadone to the applied pharmacotherapy produced a satisfactory analgesic effect and a
significant functional improvement (an ability to move around without increased pain) as well as ensured
a better quality of patient’s life.

Article available in PDF format

View PDF Download PDF file

References

  1. Mercadante S, Bruera E. Opioid switching in cancer pain: From the beginning to nowadays. Crit Rev Oncol Hematol. 2016; 99: 241–248.
  2. Fallon M, Giusti R, Aielli F, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(Suppl 4): iv166–iv191.
  3. Porta-Sales J, Garzón-Rodríguez C, Villavicencio-Chávez C, et al. Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. Oncologist. 2016; 21(8): 981–987.
  4. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet Oncology. 2012; 13(2): e58–e68.
  5. Bolan E, Tallarida R, Pasternak G. Synergy between μ Opioid Ligands: Evidence for Functional Interactions among μ Opioid Receptor Subtypes. Journal of Pharmacology and Experimental Therapeutics. 2002; 303(2): 557–562.
  6. Fürst P, Lundström S, Klepstad P, et al. The Use of Low-Dose Methadone as Add-On to Regular Opioid Therapy in Cancer-Related Pain at End of Life: A National Swedish Survey in Specialized Palliative Care. J Palliat Med. 2020; 23(2): 226–232.
  7. Fürst P, Lundström S, Klepstad P, et al. Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment. J Palliat Med. 2018; 21(2): 177–181.
  8. Courtemanche F, Dao D, Gagné F, et al. Methadone as a Coanalgesic for Palliative Care Cancer Patients. J Palliat Med. 2016; 19(9): 972–978.
  9. Mercadante S. Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. Pain Med. 2012; 13(3): 399–404.
  10. Palat G, Chary S. Practical Guide for Using Methadone in Pain and Palliative Care Practice. Indian J Palliat Care. 2018; 24(Suppl 1): S21–S29.
  11. Mercadante S, Bruera E. Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review. J Pain Symptom Manage. 2018; 55(3): 998–1003.
  12. Sunilkumar MM, Lockman K. Practical Pharmacology of Methadone: A Long-acting Opioid. Indian J Palliat Care. 2018; 24(Suppl 1): S10–S14.
  13. Franchi S, Moschetti G, Amodeo G, et al. Do All Opioid Drugs Share the Same Immunomodulatory Properties? A Review From Animal and Human Studies. Front Immunol. 2019; 10: 2914.
  14. Sande TA, Laird BJA, Fallon MT. The Management of Opioid-Induced Nausea and Vomiting in Patients with Cancer: A Systematic Review. J Palliat Med. 2019; 22(1): 90–97.
  15. Mancini IL, Hanson J, Neumann CM, et al. Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med. 2000; 3(1): 49–56.
  16. Daeninck PJ, Bruera E. Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases. J Pain Symptom Manage. 1999; 18(4): 303–309.
  17. Moulin D, Boulanger A, Clark AJ, et al. Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014; 19(6): 328–335.
  18. Mercadante S, Prestia G, Adile C, et al. Changes of QTc interval after opioid switching to oral methadone. Support Care Cancer. 2013; 21(12): 3421–3424.
  19. Flory JH, Wiesenthal AC, Thaler HT, et al. Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain. J Pain Symptom Manage. 2016; 51(1): 79–87.e1.
  20. Ikegaki J, Kizawa Y. Delirium Prolonged for Three Days after Addition of One Dose of 5 mg Methadone to Ongoing Opioid. J Palliat Med. 2020; 23(2): 164.
  21. Moksnes K, Dale O, Rosland JH, et al. How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial. Eur J Cancer. 2011; 47(16): 2463–2470.
  22. Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? Journal of Clinical Oncology. 1998; 16(10): 3216–3221.
  23. Nicholson AB, Watson GR, Derry S, et al. Methadone for cancer pain. Cochrane Database Syst Rev. 2017; 2: CD003971.
  24. Chalker C, O'Neill H, Cranfield F. Efficacy of low-dose and/or adjuvant methadone in palliative medicine. BMJ Support Palliat Care. 2019 [Epub ahead of print].